Sarah E Seton-Rogers

List of Publications by Year
in descending order

117	919	840776	580821
papers	citations	11 h-index	25 g-index

179	179	179	2068
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Cooperation of the ErbB2 receptor and transforming growth factor Â in induction of migration and invasion in mammary epithelial cells. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 1257-1262.	7.1	222
2	Delving deeper into resistance. Nature Reviews Cancer, 2014, 14, 7-7.	28.4	157
3	Untangling EMT's functions. Nature Reviews Cancer, 2016, 16, 1-1.	28.4	57
4	Multitasking hyaluronic acid. Nature Reviews Cancer, 2012, 12, 228-228.	28.4	19
5	The cancer X factor. Nature Reviews Cancer, 2013, 13, 224-225.	28.4	19
6	Gender differences. Nature Reviews Cancer, 2014, 14, 579-579.	28.4	18
7	VEGF promotes stemness. Nature Reviews Cancer, 2011, 11, 831-831.	28.4	16
8	siRNAs jump the hurdle. Nature Reviews Cancer, 2012, 12, 376-377.	28.4	15
9	ErbB2 and TGF-beta: A Cooperative Role in Mammory Tumor Progression?. Cell Cycle, 2004, 3, 595-598.	2.6	14
10	HIF switch. Nature Reviews Cancer, 2011, 11, 391-391.	28.4	14
11	ErbB2 and TGF-beta: a cooperative role in mammary tumor progression?. Cell Cycle, 2004, 3, 597-600.	2.6	14
12	Finding a rare variant. Nature Reviews Cancer, 2012, 12, 1-1.	28.4	11
13	All eyes on YAP1. Nature Reviews Cancer, 2014, 14, 515-515.	28.4	11
14	Pushing pancreatic cancer to take off. Nature Reviews Cancer, 2012, 12, 739-739.	28.4	10
15	Signalling in transit. Nature Reviews Cancer, 2012, 12, 5-5.	28.4	10
16	Means of resistance. Nature Reviews Cancer, 2013, 13, 607-607.	28.4	10
17	Teaching old macrophages new tricks. Nature Reviews Cancer, 2013, 13, 753-753.	28.4	10
18	Fibroblast co-conspirators. Nature Reviews Cancer, 2011, 11, 759-759.	28.4	9

#	Article	IF	Citations
19	Dendritic cell switch. Nature Reviews Cancer, 2012, 12, 231-231.	28.4	9
20	APC restores order. Nature Reviews Cancer, 2015, 15, 454-455.	28.4	9
21	Primed for a response. Nature Reviews Cancer, 2015, 15, 258-259.	28.4	9
22	Cancer stem cell knockout. Nature Reviews Cancer, 2014, 14, 452-453.	28.4	8
23	A circuitous way to target p53. Nature Reviews Cancer, 2015, 15, 318-319.	28.4	8
24	Different roads to inactivation. Nature Reviews Cancer, 2009, 9, 610-611.	28.4	7
25	Field effect. Nature Reviews Cancer, 2012, 12, 508-509.	28.4	7
26	Endothelial cells create a niche. Nature Reviews Cancer, 2014, 14, 298-298.	28.4	7
27	Direct hit on mutant RAS. Nature Reviews Cancer, 2014, 14, 8-9.	28.4	7
28	Driving force. Nature Reviews Cancer, 2011, 11, 539-539.	28.4	6
29	Opposing forces in invasion. Nature Reviews Cancer, 2011, 11, 625-625.	28.4	6
30	Dynamic interactions. Nature Reviews Cancer, 2012, 12, 378-379.	28.4	6
31	BETting on epigenetic therapy. Nature Reviews Cancer, 2014, 14, 385-385.	28.4	6
32	Feed it forward. Nature Reviews Cancer, 2011, 11, 461-461.	28.4	5
33	New connections. Nature Reviews Cancer, 2012, 12, 321-321.	28.4	5
34	Navigating uncharted territory. Nature Reviews Cancer, 2012, 12, 151-151.	28.4	5
35	Easily moulded. Nature Reviews Cancer, 2013, 13, 519-519.	28.4	5
36	PTEN surprise. Nature Reviews Cancer, 2013, 13, 520-520.	28.4	5

#	Article	IF	Citations
37	Hippo promotes microRNA processing. Nature Reviews Cancer, 2014, 14, 217-217.	28.4	5
38	Place your BETs. Nature Reviews Cancer, 2015, 15, 638-638.	28.4	5
39	Editing changes the meaning. Nature Reviews Cancer, 2012, 12, 797-797.	28.4	4
40	Combinations that work. Nature Reviews Cancer, 2012, 12, 231-231.	28.4	4
41	Destroying leukaemia stem cell habitats. Nature Reviews Cancer, 2013, 13, 821-821.	28.4	4
42	Making connections. Nature Reviews Cancer, 2013, 13, 222-223.	28.4	4
43	Coming in waves. Nature Reviews Cancer, 2013, 13, 379-379.	28.4	4
44	A clearer pathway view. Nature Reviews Cancer, 2014, 14, 156-157.	28.4	4
45	A cooperative tumour cell community. Nature Reviews Cancer, 2014, 14, 294-294.	28.4	4
46	Untangling the role of progesterone receptors. Nature Reviews Cancer, 2015, 15, 456-456.	28.4	4
47	Super-enhanced. Nature Reviews Cancer, 2015, 15, 4-5.	28.4	4
48	Cytokine cues. Nature Reviews Cancer, 2011, 11, 690-690.	28.4	3
49	Catabolic effects. Nature Reviews Cancer, 2011, 11, 757-757.	28.4	3
50	Epigenetic therapy gains momentum. Nature Reviews Cancer, 2012, 12, 799-799.	28.4	3
51	Tumours have a lot of nerve. Nature Reviews Cancer, 2013, 13, 608-609.	28.4	3
52	Elongation is essential. Nature Reviews Cancer, 2014, 14, 765-765.	28.4	3
53	Stressed to bits. Nature Reviews Cancer, 2015, 15, 320-320.	28.4	3
54	Order matters. Nature Reviews Cancer, 2015, 15, 196-197.	28.4	3

#	Article	IF	Citations
55	MYC maintains high-fidelity splicing. Nature Reviews Cancer, 2015, 15, 385-385.	28.4	3
56	A matter of timing. Nature Reviews Cancer, 2015, 15, 256-257.	28.4	3
57	An exhausting metabolic competition. Nature Reviews Cancer, 2015, 15, 573-573.	28.4	3
58	Model refinement. Nature Reviews Cancer, 2015, 15, 511-511.	28.4	3
59	One of these things is not like the others. Nature Reviews Cancer, 2016, 16, 5-5.	28.4	3
60	Flexible flux. Nature Reviews Cancer, 2011, 11, 621-621.	28.4	2
61	Layers of regulation. Nature Reviews Cancer, 2011, 11, 689-689.	28.4	2
62	Recharging with COCO. Nature Reviews Cancer, 2012, 12, 655-655.	28.4	2
63	Transforming fusions induce aneuploidy. Nature Reviews Cancer, 2012, 12, 585-585.	28.4	2
64	Mutational consequences. Nature Reviews Cancer, 2012, 12, 450-451.	28.4	2
65	Merlin and ezrin get organized. Nature Reviews Cancer, 2013, 13, 76-76.	28.4	2
66	An accommodating host. Nature Reviews Cancer, 2013, 13, 145-145.	28.4	2
67	Two steps ahead. Nature Reviews Cancer, 2013, 13, 383-383.	28.4	2
68	A pre-leukaemic reservoir. Nature Reviews Cancer, 2014, 14, 212-212.	28.4	2
69	A clearer pathway view. Nature Reviews Drug Discovery, 2014, 13, 177-177.	46.4	2
70	Uncovering new functions of PI3K mutations. Nature Reviews Cancer, 2014, 14, 766-767.	28.4	2
71	Source influences function. Nature Reviews Cancer, 2014, 14, 705-705.	28.4	2
72	A better mimic. Nature Reviews Cancer, 2014, 14, 75-75.	28.4	2

#	Article	IF	Citations
73	Chromatin reorganization on a 'mega' scale. Nature Reviews Genetics, 2015, 16, 499-499.	16.3	2
74	From the editors. Nature Reviews Cancer, 2006, 6, 573-573.	28.4	1
75	Model building. Nature Reviews Cancer, 2011, 11, 387-387.	28.4	1
76	Location, location, location. Nature Reviews Cancer, 2011, 11, 462-463.	28.4	1
77	Another tool in the BCRâ€“ABL kit?. Nature Reviews Cancer, 2011, 11, 833-833.	28.4	1
78	Lines of communication. Nature Reviews Cancer, 2012, 12, 580-581.	28.4	1
79	Layered regulation. Nature Reviews Cancer, 2012, 12, 737-737.	28.4	1
80	Tumour cells in reverse. Nature Reviews Cancer, 2012, 12, 794-794.	28.4	1
81	What's the alternative?. Nature Reviews Cancer, 2012, 12, 80-81.	28.4	1
82	A powerful model. Nature Reviews Cancer, 2013, 13, 8-9.	28.4	1
83	Seeing the big picture. Nature Reviews Cancer, 2013, 13, 683-683.	28.4	1
84	ALL-important mutations. Nature Reviews Cancer, 2013, 13, 151-151.	28.4	1
85	Double trouble. Nature Reviews Cancer, 2013, 13, 6-7.	28.4	1
86	Fuelling the debate. Nature Reviews Cancer, 2013, 13, 223-223.	28.4	1
87	Methylation reboot. Nature Reviews Cancer, 2013, 13, 292-292.	28.4	1
88	At the starting line. Nature Reviews Cancer, 2013, 13, 296-297.	28.4	1
89	Change in schedule. Nature Reviews Cancer, 2014, 14, 153-153.	28.4	1
90	Competition can be a good thing. Nature Reviews Cancer, 2014, 14, 381-381.	28.4	1

#	Article	IF	Citations
91	Notch blocks bladder tumorigenesis. Nature Reviews Cancer, 2014, 14, 649-649.	28.4	1
92	Feeding the beast. Nature Reviews Cancer, 2015, 15, 134-134.	28.4	1
93	Mutant relationships. Nature Reviews Cancer, 2015, 15, 135-135.	28.4	1
94	Changing shape. Nature Reviews Cancer, 2015, 15, 71-71.	28.4	1
95	Primed for a response. Nature Reviews Drug Discovery, 2015, 14, 312-312.	46.4	1
96	Building bridges. Nature Reviews Cancer, 2015, 15, 199-199.	28.4	1
97	Promoting tolerance. Nature Reviews Immunology, 2010, 10, 292-292.	22.7	0
98	Putting the brakes on lipid loss. Nature Reviews Cancer, 2011, 11, 536-536.	28.4	0
99	Suppressive EPH-ect. Nature Reviews Cancer, 2011, 11, 829-829.	28.4	0
100	Domino effect. Nature Reviews Cancer, 2012, 12, 506-506.	28.4	0
101	The new normal. Nature Reviews Cancer, 2012, 12, 660-661.	28.4	0
102	Pump up the volume. Nature Reviews Cancer, 2012, 12, 583-583.	28.4	0
103	Scheduled delivery. Nature Reviews Cancer, 2012, 12, 155-155.	28.4	0
104	No cohesion for cohesin's role. Nature Reviews Cancer, 2013, 13, 825-825.	28.4	0
105	Improved detection. Nature Reviews Cancer, 2013, 13, 150-151.	28.4	0
106	Metabolic block. Nature Reviews Cancer, 2013, 13, 440-441.	28.4	0
107	Taking it all in. Nature Reviews Cancer, 2013, 13, 438-438.	28.4	0
108	Two might not be better. Nature Reviews Cancer, 2014, 14, 646-646.	28.4	0

#	Article	IF	Citations
109	Carving out a niche. Nature Reviews Cancer, 2014, 14, 516-516.	28.4	0
110	Working in groups. Nature Reviews Cancer, 2014, 14, 645-645.	28.4	0
111	Fine-tuning metabolism. Nature Reviews Cancer, 2014, 14, 705-705.	28.4	0
112	Order matters. Nature Reviews Genetics, 2015, 16, 193-193.	16.3	0
113	An influential delivery. Nature Reviews Cancer, 2015, 15, 386-386.	28.4	0
114	Stress management by the FA pathway. Nature Reviews Cancer, 2015, 15, 699-699.	28.4	0
115	Exploring origins and evolution. Nature Reviews Cancer, 2015, 15, 68-69.	28.4	0
116	Chromatin reorganization on a 'mega' scale. Nature Reviews Cancer, 2015, 15, 513-513.	28.4	0
117	Tracking early tumour cells. Nature Reviews Cancer, 2016, 16, 69-69.	28.4	0